Ovid Therapeutics

Biopharma Ovid Therapeutics develops pioneering epilepsy and seizure‑related therapies, including Phase 1 GABA‑AT inhibitor OV329 and KCC2 activator OV350. With collaborations across AstraZeneca, Lundbeck and Healx, the firm targets high‑impact neurological markets.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 23
HQ: New York

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
OVID	Ovid Therapeutics Cap: 0.1B	EQUITY	NMS	USD	US6904691010	Active	📈